Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities
April 06 2021 - 8:00AM
Business Wire
Partnership will provide access to Valence’s
machine learning platform to accelerate preclinical drug discovery
efforts
Charles River Laboratories International, Inc. (NYSE: CRL) and
Valence Discovery today announced the formation of a strategic
partnership to provide clients access to Valence’s artificial
intelligence platform for molecular property prediction, generative
chemistry, and multiparameter optimization.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210406005112/en/
Building on research done by Valence’s founding team at Mila,
the world’s largest deep learning research institute, the Valence
platform enables the design of small molecule drug candidates in
novel regions of chemical space, followed by rapid optimization
against project-specific potency, selectivity, safety, and
pharmacology criteria. Valence has pioneered the application of
few-shot learning in drug design, allowing the company to unlock
prediction tasks for which only small amounts of training data are
available, overcoming a critical limitation of existing machine
learning technologies in drug discovery.
Partnering to Accelerate Discoveries
By combining best-in-class machine learning technologies with
Charles River’s end-to-end capabilities, the alliance has the
potential to significantly accelerate discovery efforts from hit
design through lead optimization.
Through the collaboration, Charles River clients will have the
option to access Valence’s platform to support their drug discovery
efforts. When taking advantage of this option, clients can expect
increased diversity in chemical matter being investigated, in
combination with more rapid optimization against complex,
project-specific design criteria, ultimately reducing timelines and
improving success rates for drug discovery projects.
Approved Quotes
- “This collaboration reflects Charles River’s ongoing commitment
to enhancing our portfolio of innovative technology solutions. We
look forward to leveraging Valence’s unique platform to improve
outcomes for our clients.” – Birgit Girshick, Corporate Executive
Vice President, Discovery and Safety Assessment, Biologics Testing
Solutions, and Avian Vaccine Services, Charles River
- “The Valence platform offers a step-change improvement over
existing de novo design technologies. We’ve been consistently
impressed by Valence Discovery’s ability to generate high quality
chemical matter that’s readily synthesizable, in novel regions of
chemical space, from datasets not otherwise accessible to machine
learning methods.” – Grant Wishart, PhD, Director of Computer Aided
Drug Design, Charles River
- “We are thrilled to be partnering with Charles River, a global
leader trusted by many of the world’s top pharmaceutical and
biotech companies. This collaboration is an important step in
furthering our mission of empowering every drug discovery scientist
with the latest innovations in AI-enabled drug design.”– Daniel
Cohen, CEO of Valence Discovery
About Valence’s AI-Enabled Drug Design Platform
The Valence platform expands upon academia-leading research done
by the company’s founding team at Mila, the world’s largest deep
learning research institute. In particular, Valence has pioneered
the application of few-shot learning in drug design, allowing the
company to unlock prediction tasks for which only small amounts of
training data are available, including novel targets and complex
ADME criteria, while also ensuring that AI-generated molecules are
of high medicinal chemistry quality and readily synthesizable. In
addition, Valence uses active learning and iterative optimization
strategies to ensure that only the most information-rich compounds
are selected for synthesis, enabling the design of compounds
meeting the target potency, selectivity, and ADME criteria in fewer
iterations, and with far less data, than otherwise possible.
About Valence Discovery
Valence is committed to unlocking the true potential of deep
learning in drug design by unifying best-in-class deep learning
technologies with intuitive infrastructure to make these
technologies more broadly accessible to R&D organizations of
all sizes. Valence’s AI-enabled drug design platform has been
extensively validated and is currently being used to identify and
design drug candidates in collaboration with industry-leading
partners. The company is pioneering the application of few-shot
learning in drug design and is developing and deploying novel
machine learning methods for molecular property prediction,
generative chemistry, and multiparameter optimization. Valence
(formerly InVivo AI) was founded in 2018, is advised by deep
learning pioneer, Dr. Yoshua Bengio, and is proudly headquartered
in Montreal at Mila, the world’s largest deep learning research
institute, with an office in Cambridge, Mass. To learn more, please
visit www.valencediscovery.com.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their
research and drug development efforts. Our dedicated employees are
focused on providing clients with exactly what they need to improve
and expedite the discovery, early-stage development and safe
manufacture of new therapies for the patients who need them. To
learn more about our unique portfolio and breadth of services,
visit www.criver.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210406005112/en/
Charles River Investor Contact: Todd Spencer Corporate
Vice President, Investor Relations +1-781-222-6455
todd.spencer@crl.com Charles River Media Contact: Amy
Cianciaruso Corporate Vice President, Public Relations
+1-781-222-6168 amy.cianciaruso@crl.com Valence Corporate
Contact: Therence Bois Chief Operating Officer, Valence
Discovery hello@valencediscovery.com Valence Media Contact:
Jessica Yingling, Ph.D. Little Dog Communications Inc.
jessica@litldog.com +1-858-344-8091
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Apr 2023 to Apr 2024